UK Revokes Marketing Authorization for Valneva's Chikungunya Vaccine
VALN sits 18% above its 52-week low of $4.75 on light trading volume (0.3× avg).
Summary
The UK's Medicines and Healthcare products Regulatory Agency has revoked the marketing authorization for Valneva's chikungunya vaccine, IXCHIQ. This removes a key revenue stream in a major market and raises questions about the vaccine's safety or efficacy profile. The news follows a first-half 2026 net loss of €63.3 million, triple the prior-year loss, and comes just weeks after the European Medicines Agency accepted the Lyme disease vaccine candidate for review. The revocation is a material setback for Valneva's commercial portfolio and could pressure the stock further.
At the time of this announcement, VALN was trading at $5.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $547.7M. The 52-week trading range was $4.75 to $12.18. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.